

Express Mail No. EU 821 024 242 US  
Date of Deposit: January 13, 2003

# COPY













Modified Form 1449/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)	<b>Application Number</b>	09/918,589
	<b>Filing Date</b>	July 30, 2001
	<b>First Named Inventor</b>	Cale H. Halbleib
	<b>Group Art Unit</b>	1632
	<b>Examiner Name</b>	Not Yet Assigned
	<b>Attorney Docket Number</b>	PV/17 US

U.S. PATENT DOCUMENTS							
Exam Initials	Cite No.	U.S. Patent Document No.	Issue Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date If Appropriate
	A1	6,218,128	04/17/2001	Allergan Sales			
	A2	4,045,420	08/30/1977	Syva Company			29-May-1973
	A3	4,331,808	05/25/1982	Miles Laboratories, Inc.			05-Oct-1982
	A4	4,420,568	13-Dec-1983	Abbott Laboratories			30-Nov-1981
	A5	4,585,862	29-Apr-1986	Abbott Laboratories			08-Feb-1984
	A6	4,668,640	26-May-1987	Abbott Laboratories			02-May-1985
	A7	5,573,904	12-Nov-1996	Abbott Laboratories			22-May-1995
	A8	5,097,097	17-Mar-1992	Abbott Laboratories			30-Jun-1989
	A9	5,492,841	20-Feb-1996	E. I. Du Pont de Nemours and Company			18-Feb-1994
	A10	5,804,395	08-Sep-1998	The U.S. of America as represented by the Secretary of the Navy			01-Dec-1995


FOREIGN PATENT DOCUMENTS						
Exam Initials	Cite No.	Foreign Patent Document Office Number	Name of Patentee(s) or Applicant(s)	Date of Publication	Translation Yes No	
B1		WO 01/73434	Allergan Sales, Inc.			
B2		WO 99/18124	Merck & Co., Inc.			
B3		WO 99/27365	Tularik, Inc.			
B4		EP 0 672 191 B	PanVera Corporation			
B5		WO 98/05962	PanVera Corporation			

OTHER NON-PATENT LITERATURE DOCUMENTS							
Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.					
	C1	Fernandes, P.B., "Technological advances in high-throughput screening," <i>Curr. Opin. Chem. Biol.</i> , 2(5):597-603 (1998).					
	C2	Silverman, L., et al., "New assay technologies for high-throughput screening," <i>Curr. Opin. Chem. Biol.</i> , 2(3):397-403 (1998).					
	C3	Sittampalam, G.S., et al., "High-throughput screening: advances in assay technologies," <i>Curr. Opin. Chem. Biol.</i> , 1(3):384-391 (1997).					
	C4	Lee, P. H. and Bevis, D. J., "Development of a homogeneous high throughput fluorescence polarization assay for G protein-coupled receptor binding," <i>J. Biomol. Screen.</i> , 5(6):415-419 (2000).					
	C5	Choi, M. J., et al., "Fluorescence polarization immunoassay of progesterone," <i>Biol. Pharm. Bull.</i> 20(4):309-314 (1997).					
	C6	Tota, M. R., et al., "Interaction of [fluorescein-Trp <sup>25</sup> ] glucagon with the human glucagon receptor expressed in <i>Drosophila</i> Schneider 2 cells," <i>J. Biol. Chem.</i> , 270(44):26466-26472 (1995).					
	C7	Casali, E., et al., "Fluorescence investigation of the sex steroid binding protein of rabbit serum: steroid binding and subunit dissociation," <i>Biochem.</i> , 29(40):9334-9343 (1990).					

COPY

OTHER NON-PATENT LITERATURE DOCUMENTS		
Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.
	C8	Ou, J., et al., "Unsaturated fatty acids inhibit transcription of the sterol regulatory element-binding protein-1c (SREBP-1c) gene by antagonizing ligand-dependent activation of the LXR," <i>Proc. Natl. Acad. Sci.</i> , 98(11):6027-6032 (2001).
	C9	Banks, P., et al., "Impact of a red-shifted dye label for high throughput fluorescence polarization assays for G protein-coupled receptors," <i>J. Biomol. Screen</i> , 5(5):329-334 (2000).
	C10	Nikov, G. N., et al., "Interactions of dietary estrogens with human estrogen receptors and the effect on estrogen receptor-estrogen response element complex," <i>Environ. Health Perspect.</i> , 108(9):867-872 (2000).
	C11	Saito, K., et al., "Lack of Significant estrogenic or antiestrogenic activity of pyrethroid insecticides in three <i>in vitro</i> assays based on classic estrogen receptor alpha-mediated mechanisms," <i>Toxicol. Sci.</i> , 57(1):54-60 (2000).
	C12	Parker, G. J., et al., "Development of high throughput screening assays using fluorescence polarization: nuclear receptor-ligand-binding and kinase/phosphatase assays," <i>J. Biomol. Screen</i> 5(2):77-88 (2000).
	C13	Bolger, R., et al., "Rapid screening of environmental chemicals for estrogen receptor binding capacity," <i>Environ. Health Perspect.</i> , 106(9):551-557 (1998).
	C14	PanVera Corp., Fluorescence Polarization Application Guide, Copyright 1998 Section 5
	C15	Hwang, K. J., et al., "Donor-acceptor tetrahydrochrysenes, inherently fluorescent high-affinity ligands for the estrogen receptor: binding and fluorescence characteristics and fluorometric assay of receptor," <i>Biochem.</i> , 31(46):11536-11545 (1992).
	C16	Schultz, J. R., et al., "Role of LXRs in control of lipogenesis," <i>Genes &amp; Dev.</i> , 14(22):2831-2838
	C17	Heery, D. M., et al., "A signature motif in transcriptional co-activators mediates binding to nuclear receptors," <i>Nature</i> , 387(6634):733-736 (1997).
	C18	Heery, D. M., et al., "Core LXXLL motif sequences in CREB-binding protein, SRC1, and RIP140 define affinity and selectivity for steroid and retinoid receptors," <i>J. Biol. Chem.</i> , 276(9):6695-6702 (2001).
	C19	Checovich, W. J., et al., "Fluorescence Polarization - a new tool for cell and molecular biology," <i>Nature</i> , 375(6528):254-256 (1995).
	C20	Ozers, M. S., et al., "Equilibrium Binding of Estrogen Receptor with DNA Using Fluorescence Anisotropy," <i>J. Biol. Chem.</i> , 272(48):30405-30411 (1997).

\* a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, U.S.S.N. \_\_\_\_\_, filed \_\_\_\_\_, and relied upon for an earlier filing date under 35 U.S.C. §120 (continuation, continuation-in-part, and divisional applications).

Examiner Signature		Date Considered	3-19-04
-----------------------	---	--------------------	---------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered.

Include copy of this form with next communication to applicant.